U.S.-based medical device company Boston Scientific (BSX.N) announced on Monday that it has invested $1.5 billion in privately held MiRus LLC in exchange for a 34% ownership stake and potential access to the startup’s heart-valve technology business.
The agreement signals Boston Scientific’s return to the balloon-expandable transcatheter aortic valve replacement (TAVR) market, which focuses on devices used to treat certain heart-related conditions. The company had previously exited the segment in May last year, citing growing clinical and regulatory challenges associated with the business.
- Boston Scientific stated that it could fully acquire the TAVR business of MiRus LLC through additional cash payments worth up to $3 billion, provided the company achieves specific clinical and regulatory milestones. MiRus may also receive extra payments linked to the future commercial performance and sales of the device.
- TAVR, or transcatheter aortic valve replacement systems, are designed to treat patients suffering from severe aortic stenosis a condition in which the heart’s aortic valve narrows, limiting proper blood flow throughout the body.
- MiRus is currently developing the experimental SIEGEL valve, a heart-valve device that has not yet received commercial approval in any country.
- Cardiac device products represent a major portion of Boston Scientific’s overall revenue, supported by successful technologies such as the Farapulse and Watchman systems.
- As part of the agreement, Boston Scientific also secured an option to acquire selected mitral and tricuspid valve assets from MiRus through an additional future payment arrangement.
- The company further noted that the investment is expected to have only a minimal impact on its adjusted earnings per share for 2026.
